Study of FHND1002 for people with early ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests an investigational oral medication, FHND1002, for people with ALS whose disease has been progressing for less than 2 years. It aims to slow further decline in muscle function and breathing ability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with ALS (Amyotrophic Lateral Sclerosis) and it has been less than 2 years since your first symptoms started.
- Your ALS is getting worse steadily (at least a 0.5 point drop per month on a standard rating scale).
- You have good lung function (FVC test shows 70% or more of normal) and you do NOT use a breathing machine like BiPAP or a ventilator.
- You have no serious heart, liver, kidney, or other medical conditions, and you are not pregnant or planning pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called FHND1002 in healthy adults aged 18 to 45. The goal is to check its safety, how well the body tolerates it, and how it is processed. It is one of the first tests in humans.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
This trial tests an experimental oral medication called usnoflast for people with ALS. It aims to see if the drug can slow the disease's progression.
This study tests an experimental treatment called COYA 302 for ALS. It aims to see if it can slow down the worsening of muscle weakness and improve daily function. It might be an option for people in the earlier stages of ALS.
This trial tests a new drug called XT-150 for ALS. The goal is to see if it is safe and how the body handles it. It may be an option if you have had ALS symptoms for up to 3 years and have good enough lung function.
This trial tests whether FB1006 is safe and works better than usual care for treating amyotrophic lateral sclerosis (ALS). It focuses on people with relatively early ALS and good breathing function.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.